UNCY

UNCY

USD

Unicycive Therapeutics Inc. Common Stock

$4.440+0.095 (2.186%)

Real-time Price

Healthcare
Biotechnology
United States

Price Chart

Loading Chart...

Key Metrics

Market Metrics
Company Fundamentals
Trading Stats

Market Metrics

Open

$4.345

High

$4.590

Low

$4.320

Volume

0.11M

Company Fundamentals

Market Cap

78.4M

Industry

Biotechnology

Country

United States

Trading Stats

Avg Volume

0.47M

Exchange

NCM

Currency

USD

52-Week Range

Low $3.71Current $4.440High $11

Related News

GlobeNewswire

Unicycive Therapeutics to Participate in a Fireside Chat at the Guggenheim 2nd Annual Healthcare Innovation Conference

LOS ALTOS, Calif., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (NASDAQ:UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease (the "Company" or

View more
Unicycive Therapeutics to Participate in a Fireside Chat at the Guggenheim 2nd Annual Healthcare Innovation Conference
GlobeNewswire

Unicycive Therapeutics Announces Upcoming Presentation of New Data Reinforcing the Potential of Oxylanthanum Carbonate for the Treatment of Hyperphosphatemia at the American Society of Nephrology Kidney Week 2025 Conference

LOS ALTOS, Calif., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (NASDAQ:UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease (the "Company" or

View more
Unicycive Therapeutics Announces Upcoming Presentation of New Data Reinforcing the Potential of Oxylanthanum Carbonate for the Treatment of Hyperphosphatemia at the American Society of Nephrology Kidney Week 2025 Conference
Analyst Upgrades

HC Wainwright & Co. Maintains Buy on Unicycive Therapeutics, Raises Price Target to $22

HC Wainwright & Co. analyst Swayampakula Ramakanth maintains Unicycive Therapeutics with a Buy and raises the price target from $9 to $22.

View more
HC Wainwright & Co. Maintains Buy on Unicycive Therapeutics, Raises Price Target to $22
GlobeNewswire

Unicycive Therapeutics Provides Update from FDA Type A Meeting and Expects to Resubmit OLC NDA Before Year-End

LOS ALTOS, Calif., Oct. 28, 2025 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (NASDAQ:UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease (the Company or Unicycive),

View more
Unicycive Therapeutics Provides Update from FDA Type A Meeting and Expects to Resubmit OLC NDA Before Year-End
PR Newswire

UNCY Investors Have Opportunity to Lead Unicycive Therapeutics, Inc. Securities Fraud Lawsuit

Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Unicycive Therapeutics, Inc. (NASDAQ: UNCY) between March ...

View more
UNCY Investors Have Opportunity to Lead Unicycive Therapeutics, Inc. Securities Fraud Lawsuit
PR Newswire

Unicycive Therapeutics, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - UNCY

The DJS Law Group reminds investors of a class action lawsuit against Unicycive Therapeutics, Inc. ("Unicycive" or "the Company") (NASDAQ: UNCY ) for ...

PR Newswire

UNCY Investors Have Opportunity to Lead Unicycive Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm

The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Unicycive Therapeutics, Inc....